2.12
Xbiotech Inc stock is traded at $2.12, with a volume of 68,197.
It is down -1.85% in the last 24 hours and down -1.40% over the past month.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
See More
Previous Close:
$2.16
Open:
$2.16
24h Volume:
68,197
Relative Volume:
1.16
Market Cap:
$64.63M
Revenue:
$300.00K
Net Income/Loss:
$-40.16M
P/E Ratio:
-1.6092
EPS:
-1.3174
Net Cash Flow:
$-42.36M
1W Performance:
-7.42%
1M Performance:
-1.40%
6M Performance:
-12.76%
1Y Performance:
-14.86%
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
XBIT
Xbiotech Inc
|
2.12 | 64.63M | 300.00K | -40.16M | -42.36M | -1.3174 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBIT Forecast — Price Target — Prediction for 2027 - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech Inc. SEC Filing (Oct 2, 2026) - Stock Titan
$17.3M in severance is part of a former CEO's 2025 compensation at XBiotech (XBIT). - Stock Titan
Xbiotech Stock Price Forecast. Should You Buy XBIT? - StockInvest.us
XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving AverageTime to Sell? - MarketBeat
XBiotech (XBIT) Slips 4.78% to $2.19, Testing Key Support at $2.08Supply Zone - vinanet.vn
XBiotech (XBIT) Slips 4.78% to $2.19, Testing Key Support at $2.08Sector ETF Flow - careplusvn.com
XBiotech (XBIT) Slips 4.78% to $2.19, Testing Key Support at $2.08Island Reversal - dars.gov.et
XBiotech (XBIT) Slips 4.78% to $2.19, Testing Key Support at $2.08OBV Trend Line - dars.gov.et
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving AverageHere's What Happened - MarketBeat
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move - vinanet.vn
XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the CloseEarly Entry Signals - vinanet.vn
XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the CloseLinear Regression - dars.gov.et
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move: The Market Price Advances 0.65% at the CloseRevenue Growth Outlook - dars.gov.et
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move - siam.in
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move - dars.gov.et
XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the CloseMomentum ETF - careplusvn.com
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move: The Market Price Advances 0.65% at the CloseProfitability Analysis - dars.gov.et
XBiotech (XBIT) Quarter in Focus: Reported EPS Misses Expectations for This Review; Closing Move: The Market Price Advances 0.65% at the CloseEarnings Call Q&A - www.dars.gov.et
XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the CloseInitial Balance - dars.gov.et
XBiotech (XBIT) Move: Advances 0.22% to $2.30 for the Current Session; Current Setup: Price Remains Between $2.18 Support and $2.42 Resistance at the CloseBull Flag - dars.gov.et
XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS - MarketBeat
XBiotech: Q2 Earnings Snapshot - marketscreener.com
XBiotech: Q2 Earnings Snapshot - AOL.com
XBiotech: Q2 Earnings Snapshot - Enidnews.com
XBiotech: Q2 Earnings Snapshot - KTVB
XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026 - Stock Titan
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XBiotech: Q2 Earnings Snapshot - Barchart.com
XBiotech (XBIT) Earnings Date and Reports 2026 $XBIT - MarketBeat
XBiotech: Q2 Earnings Snapshot - Yahoo Finance
XBiotech (XBIT) Edges Higher at $2.28 as Stock Consolidates Between Key Support and ResistanceOverbought Signal Alerts - careplusvn.com
XBiotech (XBIT) Edges Higher at $2.28 as Stock Consolidates Between Key Support and ResistanceRip Sell Trade - dars.gov.et
XBiotech (XBIT) Edges Higher at $2.28 as Stock Consolidates Between Key Support and ResistanceActive ETF Flow - dars.gov.et
XBiotech (XBIT) Edges Higher at $2.28 as Stock Consolidates Between Key Support and ResistanceJelly Roll Trade - dars.gov.et
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech Inc (XBIT) Stock News Today - TradingKey
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat
XBiotech Inc (XBIT) Income Statement - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Balance Sheet - TradingKey
XBIT|XBiotech Inc|Price:2.300|Chg%:+0.030 - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Cash Flow - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT|XBiotech Inc|Price:2.270| - TradingKey
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):